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Blood pressure is frequently elevated, blood volume is usually normal or increased and plasma renin and aldosterone are usually low in
nephrotic syndrome (NS). These observations challenge the conventional view attributing sodium retention in NS to a hypoalbuminemia-
induced intravascular volume contraction. Given the pivotal role of nitric oxide (NO) in regulation of renal sodium (Na) handling, vascular
resistance and sympathetic activity, we considered that Na retention and hypertension in NS may be associated with impaired NO system.
Urinary excretion of Na and NO metabolites (NOx), as well as immunodetectable endothelial (eNOS), inducible (iNOS) and neuronal
(nNOS) NO synthases were determined in rats with puromycin aminonucleoside (PAN)-induced NS, rats with protein overload proteinuria,
Nagase rats (NAR) with inherited analbuminemia, iNOS inhibitor (aminoguanidine)-treated rats, prenephrotic PAN-treated and placebo-
treated control rats. The NS group showed marked proteinuria, hypoalbuminemia, decreased fractional excretion of Na (FENa), reduced
urinary NOx excretion, and severe reduction of iNOS and nNOS protein abundance in the kidney. Similar results were found in rats with
protein overload proteinuria in which proteinuria was present without hypoalbuminemia. In contrast, despite extreme hypoalbuminemia,
NAR showed normal FENa, increased urinary NOx excretion and upregulations of iNOS and nNOS protein abundance in the kidney.
Administration of aminoguanidine for 3 weeks lowered FENa in normal rats to levels approximating those found in the NS group. Animals
studied 2 days after PAN administration (wherein proteinuria was absent) showed no abnormality. Thus, chronic PAN-induced NS results in
downregulation of kidney iNOS and nNOS, which can contribute to the reduction of FENa by augmenting renal tubular Na reabsorption, and
preglomerular vasoconstriction. Findings in the NAR, which had profound hypoalbuminemia without proteinuria, and in rats with protein
overload proteinuria, which had proteinuria without hypoalbuminemia, point to proteinuria as the primary mediator of kidney iNOS and
nNOS deficiency and impaired Na excretion in PAN-induced NS.D 2003 Elsevier Science B.V. All rights reserved.Keywords: Proteinuria; Hypoalbuminemia; Nagase analbuminemic rat; Edema; Sodium excretion; Hypertension
1. Introduction sin–aldosterone cascade, augmenting sympathetic activity,Heavy glomerular proteinuria, otherwise known as neph-
rotic syndrome (NS), is marked by edema formation and
avid sodium retention. These events were initially attributed
to the reduction of plasma albumin concentration (hence,
plasma oncotic pressure) leading to a fluid shift from the
intravascular to interstitial compartment and a decline in
plasma volume. The presumed intravascular volume deple-
tion was, in turn, thought to enhance renal tubular sodium
and water reabsorption by activating the renin–angioten-0925-4439/03/$ - see front matter D 2003 Elsevier Science B.V. All rights reserv
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E-mail address: ndvaziri@uci.edu (N.D. Vaziri).stimulating vasopressin and inhibiting atrial natriuretic pep-
tide release [1]. However, validity of the classic view
outlined above has been seriously challenged by several
compelling observations which point to an, as yet, unde-
fined intrinsic abnormality of renal hemodynamics and
tubular sodium transport as opposed to hypoalbuminemia
and hypovolemia, per se. For instance, edema is generally
absent in humans and rats with congenital analbuminemia
[2,3]. In addition, plasma volume is usually normal or
elevated in patients with nephrotic syndrome [4,6]. More-
over, measurements of functional indicators of plasma
volume, such as, hematocrit or plasma concentrations of
renin, aldosterone, norepinephrine, vasopressin and atrial
natriuretic peptide have not provided consistent evidence for
presence of intravascular volume depletion in nephroticed.
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usually reduced [5–8] and plasma norepinephrine, vaso-
pressin and atrial natriuretic peptides are generally normal in
patients with nephrotic syndrome [9–11]. Moreover, natriu-
resis precedes the rise in serum albumin concentration and
plasma renin activity and aldosterone paradoxically rise
with the resolution of edema in nephrotic patients under-
going remission with steroid therapy [7]. It is also of note
that 78–95% of nephrotic patients with minimal change
disease and membranous nephropathy exhibit hypertension
during the edematous phase of the disease [12] which tends
to argue against hypovolemia. Thus, while changes in blood
volume may, in part, contribute to the associated sodium
retention and edema formation, bulk of the available evi-
dence points to a primary intrarenal defect. This is clearly
exemplified by experimental models of unilateral proteinu-
ria (induced by puromycin aminonucleoside (PAN)) and
glomerulonephritis, which show enhanced sodium reabsorp-
tion in the affected but not the intact kidney. The latter
experiments clearly point to the intrarenal, as opposed to
systemic humoral or hemodynamic factor(s) as the cause of
the abnormal sodium handling in this model [13–15].
Indirect as well as direct micropuncture studies have iden-
tified distal nephron as a potential site of altered sodium
handling in nephrotic animals [15]. The underlying mech-
anism for increased tubular Na reabsorption in nephrotic
syndrome is unknown. However, several studies have dem-
onstrated a marked renal resistance to natriuretic action of
ANP in humans [16,17] and experimental animals [18,19].
This phenomenon has been attributed to accelerated degra-
dation of second messenger, cGMP [20–22].
Nitric oxide (NO) is a ubiquitous messenger molecule
which is involved in regulation of numerous biological
functions. It is produced from stereospecific oxidation of
L-arginine by a family of enzymes known as NO synthase
(NOS). Three distinct NOS isoforms have thus far been
identified, i.e. endothelial (eNOS or NOS III) inducible
(iNOS or NOS II) and neuronal (nNOS or NOS I) isoforms.
As summarized in a recent review [23], all three NOS
isoforms are constitutively expressed in the kidney. For
instance, eNOS is abundantly expressed in the endothelial
lining of the renal arterial tree and capillaries, as well as
collecting duct epithelial cells while nNOS is heavily
expressed in the macula densa and to a lesser extent in the
efferent arterioles and epithelial cells of the thick ascending
limb, mesangial cells and intrarenal neurons. Finally, iNOS
is expressed in the epithelial cell of the thick ascending
limb, proximal tubule and collecting duct, as well as
vascular smooth muscle, mesangial and medullary intersti-
tial cells [23].
Tonic release of eNOS- and iNOS-derived NO in the
renal and systemic vasculature plays a pivotal role in the
maintenance of vasodilatory tone, thereby, regulation of
renal and systemic vascular resistance, blood pressure and
tissue perfusion. In addition, intrarenal NO serves as a major
regulator of renal sodium and water excretion and, as such,functions as an endogenous diuretic [24–26]. NO produced
by iNOS in tubular epithelial cells promotes natriuresis by
inhibiting sodium reabsorption. Moreover, NO derived from
nNOS in the macula densa attenuates tubuloglomerular
feedback-mediated afferent arteriolar vasoconstriction in
response to luminal Na content, thus, facilitating Na excre-
tion and glomerular filtration [23,27,28]. In fact, intra-
arterial administration of NOS inhibitor results in a marked
reduction of urinary sodium and water excretion and blunts
pressure natriuresis [29,30]. Moreover, systemic adminis-
tration of NOS inhibitor raises renal and systemic vascular
resistance and arterial blood pressure.
Given the pivotal role of NO in regulation of renal and
systemic hemodynamics and renal sodium handling which
are markedly deranged in nephrotic syndrome, we sought to
explore expression of NOS isoforms in the kidney, heart,
brain and vascular tissues in rats with PAN-induced neph-
rotic syndrome. In an attempt to dissect the effect of
hypoalbuminemia from that of proteinuria, rats with protein
overload proteinuria as well as rats with hereditary hypo-
albuminemia were included in the study. We chose the PAN-
induced nephrotic syndrome because it is devoid of prolif-
erative glomerular lesions [31], which can lead to cytokine-
mediated induction of iNOS in mesangial cells, and con-
found the effect of proteinuria, per se, on NOS isoform
expressions.2. Materials and methods
2.1. Study groups
Male Sprague–Dawley rats weighing 180–200 g were
housed in a temperature- and light-controlled space with 12
h light (500 lx) and dark (V 5 lx) cycles. The rats were
allowed free access to food (Purina Rat Chow, Purina Mills
Inc., Brentwood, MO, USA) and water. Animals were
randomized into the nephrotic and normal control groups.
The rats assigned to the nephrotic group received sequential
intraperitoneal injections of PAN on day 1 (130 mg/kg) and
day 14 (60 mg/kg). The rats assigned to the control group
received placebo injections of 5% dextrose in water. In an
attempt to dissect the possible effect of proteinuria from that
of hypoalbuminemia, two additional animal models were
employed. First, a group of male age-matched Nagase
hypoalbuminemic rats (Japan SLC Inc., Hamamatsu, Japan)
which exhibit profound hypoalbuminemia without protei-
nuria. Second, a group of male Sprague–Dawley rats with
protein overload proteinuria which show proteinuria without
hypoalbuminemia. The animals employed in this group
were given intraperitoneal injections of lipid-free bovine
serum albumin (Sigma Chemical Co, St. Louis, MO) 1 g/rat/
day for 8 days and studied on day 9. Thirty days after the
initial PAN or placebo injections, animals (n = 6 per group)
were placed in individual metabolic cages for a 24-h urine
collection. Blood pressure was measured by tail plethys-
Fig. 1. Fractional excretion of sodium (FENa) and systolic arterial pressure
in the normal control group (CTL), rats with puromycin-induced nephrotic
syndrome (NS), Nagase rats with hereditary analbuminemia (NAR), rats
with protein overload proteinuria (POP), Aminoguanidine-treated controls
(AG), and prenephrotic rats studied 2 days after puromycin administration
(PAN). n= 6 in each group, *P< 0.05 versus the control group.
Fig. 2. Representative Western blots and group data depicting eNOS, iNOS
and nNOS protein abundance in the kidneys of the nephrotic (NS) group
(upper panels), rats with protein overload proteinuria (POP, lower panels),
and Nagase rats with inherited hypoalbuminemia (NAR, middle panels)
compared to the control group. *P < 0.01 versus control group, n= 6 in each
group.
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intake was monitored during the last week of the observa-
tion period and was found to be comparable in the three
groups. At the conclusion of the observation period, under
general anesthesia (thiobutabarbital 100 mg/kg, IP) animals
were euthanized by exsanguination; and brain, kidney,
thoracic aorta and heart were harvested. The tissues were
immediately cleaned then frozen in liquid nitrogen and
stored at  70 jC until processed.
In order to dissect the effect of nephrotic syndrome from
that of PAN, per se, a subgroup of prenephrotic rats was
studied 2 days after IP injection of 130 mg of PAN, at which
point urinary protein excretion was normal. Moreover, in
order to discern the possible role of iNOS, which was
severely reduced in the nephrotic animals, a group of normal
rats was treated with the reputed iNOS inhibitor, amino-
guanidine (hemisulfate salt of aminoguanidine, 500 mg/dl in
the drinking water) for 3 weeks.
2.2. Measurement of total nitrate and nitrite (NOx)
The concentration of NOx in the test samples was
determined by means of the Sievers Instruments Model
270B Nitric Oxide Analyzer (NOAk, Sievers Instruments,
Boulder, CO) as described in our earlier studies [33].2.3. Measurements of tissue NOS isoforms
Frozen tissues were processed for determination of en-
dothelial (eNOS), inducible (iNOS) and neuronal (nNOS)
NOS protein abundance using anti eNOS, iNOS and nNOS
monoclonal antibodies (Transduction Laboratories, Lexing-
ton, KY) as described in our previous studies [34–36].
Briefly, thoracic aorta, kidney, left ventricle, and brain were
homogenized (25% wt/vol) in 10 mmol/l HEPES buffer, pH
7.4, containing 320 mmol/l sucrose, 1 mmol/l EDTA, 1
mmol/l DTT, 10 mg/ml leupeptin, and 2 mg/ml aprotinin at
0–4 jC with a tissue grinder fitted with a motor-driven
ground glass pestle. Homogenates were centrifuged at
12,000 g for 5 min at 4 jC to remove tissue debris with-
out precipitating plasma membrane fragments. The super-
natant was used for determination of NOS proteins. Total
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Fig. 3. Representative Western blots and group data depicting eNOS and
iNOS protein abundance in the thoracic aorta of the nephrotic (NS) group
(upper panels), rats with protein overload proteinuria (POP, lower panels),
and Nagase rats with inherited hypoalbuminemia (NAR, middle panels)
compared to the control group. *P < 0.01 versus control group, n= 6 in each
group.
Fig. 4. Representative Western blots and group data depicting eNOS and
iNOS protein abundance in the left ventricle of the nephrotic (NS) group
(upper panels), rats with protein overload proteinuria (POP, lower panels),
and Nagase rats with inherited hypoalbuminemia (NAR, middle panels)
compared to the control group. *P< 0.01 versus control group, n= 6 in each
group.
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Rad kit (Bio-Rad Laboratories, Hercules, CA). The tissue
extracts (50 Ag of protein for aorta and heart and 100 Ag
protein for kidney and brain) were size-fractionated on 4–
12% Tris–glycine gel (Novex, Inc., San Diego, CA) at 120
V for 3 h. After electrophoresis, proteins were transferred
onto hybond-ECL membrane (Amersham Life Science Inc.,
Arlington Heights, IL) at 400 mA for 120 min with the
Novex transfer system. In preliminary experiments, we had
found that the given protein concentrations were within the
linear range of detection for our Western blot technique. The
membrane was prehybridized in 10 Al of buffer A (10mmol/l Tris–HCl, pH 7.5, 100 mmol/l NaCl, 0.1% Tween
20, and 10% nonfat milk powder) for 1 h and then
hybridized for an additional 1-h period in the same buffer
containing 10 Al of the given anti-NOS monoclonal anti-
body (1:1000). The membrane was then washed for 30 min
in a shaking bath, and the wash buffer (buffer A without
nonfat milk) was changed every 5 min before 1 h of
incubation in buffer A plus goat anti-mouse IgG/horseradish
peroxidase at the final titer of 1:1000. Experiments were
performed at room temperature. The washes were repeated
before the membrane was developed with a light-emitting
nonradioactive method with the use of ECL Western blot
detection reagent (Amersham Life Science). The membrane
was then subjected to autoluminography for 10 s. The
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(model PD1211, Molecular Dynamics) to determine the
relative optical densities of the bands. In all instances, the
membranes were stained with Ponceau stain, which verified
the uniformity of protein load and transfer efficiency across
the test samples.
2.4. Miscellaneous tests
Plasma albumin, urinary protein excretion and plasma
and urine concentrations of creatinine, sodium and chloride
were measured using standard laboratory methods. Frac-
tional excretions (FE) of sodium and chloride were calcu-
lated by dividing their respective clearances by creatinine
clearance.
2.5. Data analysis
Data are expressed as meanF S.E. Analysis of variance
(ANOVA), multiple range test, regression analysis and
Student’s t-test were used as appropriate. P values less than
0.05 were considered significant.3. Results
3.1. General data
As expected, the nephrotic rats exhibited heavy protei-
nuria (256F 18.2 mg/24 h versus 7.4F 0.6 mg/24 h, in the
control group, P < 0.01). This was accompanied by a
marked reduction in serum albumin concentration (2.2F
0.1 versus 3.7F 0.1 g/dl, respectively, P < 0.01). In contrast,
proteinuria (308F 15.2 mg/24 h) was accompanied by
normal serum albumin concentration (3.9F 0.2 g/dl) in ratsFig. 5. Representative Western blot and group data depicting nNOS protein abund
overload proteinuria (POP, right panel), and Nagase rats with inherited hypoalbumi
control group, n= 6 in each group.with protein overload induced proteinuria while severe
hypoalbuminemia (0.78F 0.04 g/dl, P < 0.001 versus other
groups) was associated with normal urinary protein
(7.2F 0.4 mg/24 h) in the NAR group. No significant
difference was found in serum creatinine among the study
groups (0.6F 0.01 mg/dl in the nephrotic rats, 0.7F 0.03
mg/dl in rats with protein overload proteinuria, 0.6F 0.02
mg/dl in the control group and 0.5F 0.02 mg/dl in the NAR
group). Likewise, creatinine clearance was comparable in
the four groups (1.1F 0.1, 1.3F 0.2, 1.3F 0.1 and
1.2F 0.2 ml/min, respectively, P=NS). Arterial pressure
in the nephrotic group obtained at day 30, was significantly
higher than that found in the normal control group. Sim-
ilarly, the aminoguanidine-treated group showed a mild but
significant rise in arterial pressure. Blood pressure was
elevated in the NAR group and normal in rats with protein
overload proteinuria (Fig. 1).
3.1.1. FENa and NOx excretions
The nephrotic group exhibited a significantly lower
(P < 0.01) FENa (1.21F 0.1%) compared with the control
group (1.76F 0.2%) and the NAR group (1.70F 0.1%). No
significant differences were found in the corresponding
values between the control and NAR groups. Similarly,
FENa was significantly reduced (0.7F 0.2%, P < 0.01) in
rats with protein overload proteinuria. No significant differ-
ence was found in FENa between the prenephrotic rats
studied 2 days post-PAN injection (1.6 4F 0.2%) and the
normal control group. Administration of iNOS inhibitor,
aminoguanidine, resulted in a significant (P < 0.02) reduc-
tion of FENa (0.92F 0.1%) compared with the control
animals (Fig. 1). Urinary NOx excretion obtained at the
end of the observation period was significantly lower in the
nephrotic group (0.27F 0.03 Amol/mg creatinine) than
those in the control group (0.39F 0.03 Amol/mg creatinine,ance in the brain of the nephrotic (NS) group (left panel), rats with protein
nemia (NAR, middle panel) compared to the control group. *P < 0.01 versus
Fig. 6. Representative Western blots and group data depicting eNOS, iNOS and nNOS protein abundance in prenephrotic rats studied 48 h after a single IP
injection of placebo (CTL) or puromycin aminonucleoside (PAN, 130 mg/kg). n= 6 in each group. No significant difference was found between the two
groups.
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3.2. Tissue NOS data
3.2.1. Kidney
Data are depicted in Fig. 2. The nephrotic rats and rats
with protein overload proteinuria exhibited significant
downregulations of renal tissue iNOS expression as com-
pared to those in the normal control group. In contrast, renal
tissue iNOS and nNOS proteins were significantly elevated
in the NAR group. However, no significant difference was
found in the renal tissue eNOS protein abundance between
the three groups.
3.2.2. Aorta NOS data
Data are illustrated in Fig. 3. As with the kidney tissue,
iNOS abundance in the aorta was markedly reduced in the
nephrotic rats and rats with protein overload proteinuria and
significantly increased in NAR. eNOS protein expression in
the aorta was comparable among the study groups.
3.2.3. Heart NOS data
Data are shown in Fig. 4. The nephrotic group and rats
with protein overload proteinuria showed a significant
downregulation and the NAR showed a marked upregula-
tion of iNOS protein abundance in the left ventricle. How-
ever, left ventricular tissue eNOS protein abundance was
normal in both nephrotic and NAR groups and reduced in
rats with protein overload proteinuria.
3.2.4. Brain nNOS data
Data are given in Fig. 5. Brain nNOS protein abundance
was significantly reduced in the nephrotic rats and insignif-icantly reduced in rats with protein overload proteinuria but
was normal in the NAR group.
3.2.5. Effect of PAN
Data are provided in Fig. 6. No significant difference was
found in either NOS isoforms between the normal control
group and prenephrotic rats studied 2 days after PAN
injection. These observations argue against a short-term
effect of puromycin, per se, on NOS isoform expressions
in rats with chronic PAN-induced nephrotic syndrome.4. Discussion
The nephrotic animals as well as rats with protein over-
load proteinuria exhibited a marked reduction of fractional
excretion (and hence, enhanced tubular reabsorption) of
sodium as compared with the control and NAR rats which
showed comparable values. This was accompanied by
marked downregulation of renal tissue iNOS and nNOS
abundance. In addition, heart and vascular tissue iNOS
abundance was reduced in the nephrotic animals. The
observed reduction of iNOS abundance in the kidney can
potentially contribute to enhanced tubular reabsorption of
sodium in the nephrotic animals. This viewpoint is sup-
ported by several observations: first, iNOS is constitutively
expressed in the major sites of renal sodium reabsorption
(i.e. proximal tubule, thick ascending limb and collecting
ducts) and NO is a potent inhibitor of tubular sodium
reabsorption [23]. It is, therefore, reasonable to assume that
severe downregulation of kidney tissue iNOS, may enhance
tubular reabsorption of sodium. Second, administration of
inhibitor of iNOS expression, dexamethasone confers salt
sensitivity in Dahl salt-resistant rats [37] while administra-
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salt-sensitive rats [38]. Third, a strong cosegregation of
iNOS alleles with blood pressure has been shown in the
F2 population derived from a cross of inbred salt-sensitive
Dahl rats with the normotensive Milan rats [39] suggesting
possible connection of iNOS with salt sensitivity and blood
pressure regulation. Finally, downregulation of iNOS pro-
tein expression has been found in several disorders, which
are associated with impaired salt excretion, such as salt-
sensitive hypertension [34], cyclosporine-induced hyperten-
sion [33], and chronic renal insufficiency [32]. In contrast,
extended exposure to microgravity, which causes marked
natriuresis, is associated with significant upregulation of
renal, vascular, and cardiac iNOS abundance [35]. More-
over, the hemodynamic instability frequently seen following
return to normal gravity responds favorably to administra-
tion of iNOS inhibitor, aminoguanidine [35].
Recently, Deschenes and Doucet [40] reported increased
Na–K–ATPase activity in the collecting ducts of three
different rat models of nephrotic syndrome. They, therefore,
concluded that enhanced Na–K–ATPase activity is in-
volved in sodium retention associated with nephrotic syn-
drome. It is of note that iNOS-derived NO has been shown
to markedly reduce Na–K–ATPase activity and expression
in cultured thick ascending limb of loop of Henle’s cells
over-expressing iNOS [41]. Thus, the reported upregulation
of Na–K–ATPase in nephrotic syndrome may be, in part,
due to downregulation of constitutively expressed iNOS
expression shown in the present study.
In an attempt to discern the possible contribution of
depressed iNOS abundance to Na+ retention in the NS
animals, we included a group of normal rats treated with
the reputed iNOS inhibitor, aminoguanidine for 3 weeks.
Chronic pharmacological inhibition of iNOS resulted in a
moderate rise in arterial pressure coupled with a significant
reduction in FENa in otherwise normal animals. This obser-
vation suggests that NS-induced downregulation of iNOS
may contribute to the associated Na retention.
The nephrotic animals showed a marked downregulation
of renal tissue nNOS abundance. nNOS is prominently
expressed in the macula densa and to a lesser extent in the
efferent arteriole, mesangial cells and intrarenal neurons
[23]. NO produced by nNOS in the macula densa attenuates
tubuloglomerular feedback-mediated afferent arteriolar vas-
oconstriction in response to luminal salt content [27,42,43].
Thus, downregulation of renal tissue nNOS abundance can
potentially contribute to impaired renal sodium excretion
and renal vasoconstriction by intensifying the tubuloglo-
merular feedback response. The potential role of the defec-
tive L-arginine NO system in PAN-induced nephrotic
syndrome is supported by an earlier study which demon-
strated improvements in glomerular filtration rate and his-
tological abnormalities with L-arginine administration in this
model [44].
In contrast to the nephrotic animals, the rats with
inherited hypoalbuminemia, exhibited normal FENa togetherwith marked upregulations of renal tissue iNOS and nNOS
abundance. This observation points to proteinuria as the
proximal cause of altered renal sodium handling, depressed
iNOS, and nNOS expression in nephrotic syndrome. More-
over, the study provides a potential mechanism (i.e. elevated
renal iNOS and nNOS) for normal renal sodium handling
despite extreme hypoalbuminemia in rats and humans with
inherited hypoalbuminemia [2,3]. The potential role of
proteinuria in the pathogenesis of impaired Na excretion
and altered iNOS and nNOS expression is further supported
by our findings in rats with protein overload-induced
proteinuria in whom proteinuria was present in the face of
normal serum albumin concentrations.
Our rats with chronic PAN-induced NS exhibited a
significant elevation of arterial pressure. Hypertension is a
common feature of clinical nephrotic syndrome particularly
during the edematous phase [12]. The mechanism by which
nephrotic syndrome causes hypertension is not clear. How-
ever, hypertension is frequently ameliorated by the resolu-
tion of edema with either diuretic therapy, spontaneous or
steroid-induced remission [12]. These observations point to
the partial role of hypervolemia in the pathogenesis of
hypertension in nephrotic syndrome. In addition, the
observed downregulations of cardiovascular iNOS and of
brain nNOS, shown here, can contribute to the pathogenesis
of hypertension in the nephrotic animals. iNOS is constitu-
tively expressed in the vascular smooth muscle cells [32–36]
and iNOS-derived NO directly contributes to the vasodila-
tory tone in an autocrine fashion. In addition, nNOS-derived
NO in the brain suppresses central sympathetic outflow and
hence, norepinephrine release in the vascular tissue [45–47].
Thus, downregulation of brain nNOS in nephrotic animals
can indirectly raise vascular resistance and, hence, blood
pressure by limiting the NO-mediated inhibition of central
sympathetic activity. Although rats with protein overload
proteinuria have been shown to develop salt-sensitive hyper-
tension in the chronic phase [48], blood pressure studied 1
week after induction of proteinuria was still normal. The
presence of hypertension in our rats with chronic nephrotic
syndrome and its absence in our rats with acute protein
overload proteinuria despite diminished FENa in both may be
due to differences in duration of proteinuria.
eNOS abundance in the kidney, aorta and heart was
virtually unaffected by either nephrotic syndrome or
inherited hypoalbuminemia despite moderate hypertension
which should have upregulated eNOS abundance in the
nephrotic animals by raising shear stress and cyclic strain.
Thus, the lack of discernible rise in eNOS expression in the
tested tissues may represent an inappropriate response in the
nephrotic rats.
In an attempt to discern the possible role of PAN, per se,
on the measured parameters, a group of prenephrotic ani-
mals was studied 48 h following a single PAN injection (130
mg/kg, IP) at which point proteinuria was absent. The result
showed no discernible change in either NOS isoforms or
FENa, thus excluding a possible short-term effect of PAN in
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further supported by the observed similarity in the studied
parameters between our rats with PAN-induced nephrotic
syndrome and rats with protein overload-induced proteinu-
ria. Impaired Na excretion in the latter model found here is
consistent with previously published studies [48].
In conclusion, chronic PAN-induced nephrotic syndrome
results in downregulations of kidney iNOS and nNOS,
vascular iNOS and brain nNOS, which can contribute to
the observed reduction of FENa and hypertension by pro-
moting renal tubular Na reabsorption, vasoconstriction and
central sympathetic activity. Findings in the NAR which
have profound hypoalbuminemia without proteinuria and
rats with protein overload-induced proteinuria which have
proteinuria without hypoalbuminemia point to proteinuria as
the primary mechanism of NOS deficiency and impaired Na
excretion in PAN-induced nephrotic syndrome.Acknowledgements
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